Notice NOT-MH-22-211 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-079 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-078 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-156 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This FOA will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

Funding Opportunity PAR-22-157 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This FOA will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

Funding Opportunity PAR-22-158 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This FOA will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.

Funding Opportunity PAR-22-159 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This FOA will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.

Notice NOT-MH-22-190 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-22-019 from the NIH Guide for Grants and Contracts. The NIH Directors New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important problems relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's New Innovator Award Program complements ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators through R01 grants, which continue to be the major sources of NIH support for early stage investigators. The NIH Directors New Innovator Award Program is a component of the High-Risk, High-Reward Research Program of the NIH Common Fund.

Funding Opportunity RFA-DA-23-002 from the NIH Guide for Grants and Contracts. oEnsuring all PLWH have rapid access to care, especially in resource-limited settings, remains a key challenge to the success of HIV care/treatment efforts. Same day or other rapid treatment initiation may be available, but patients may be concerned that other needs will make treatment difficult or they may face delays related to the enrollment process for treatment support mechanisms (e.g., ADAP, Ryan White, Medicaid). Similarly, long-term retention in HIV care and sustained achievement of viral suppression can be challenging even when ARV is introduced at or close to HIV diagnosis. Existing practices such as Strengths-Based Case Management and Patient Navigation often demonstrate a lack of efficacy among people with SUD. Persons with SUD and HIV often present clinical complexities and engagement with multiple services may be necessary; where reducing and eliminating barriers (i.e. structural or individual) to immediate linkage to care is critical to minimizing time between diagnosis and treatment and can lead to achieving Ending the Epidemic goals. Even with rapid ARV uptake, this population may need additional supports to remain continuously engaged in care. There is a need to develop and test evidence-based interventions at the systemic, organizational, and/or provider levels that can reduce the time between diagnosis and treatment while also retaining persons with SUD in HIV and SUD care.

Funding Opportunity RFA-MD-22-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from current Research Centers in Minority Institutions (RCMI) awardees to participate in the RCMI Clinical Research Network for Health Equity (RCMI-CRNHE), a newly established clinical research network that will transform the development, delivery, and sustainability of evidence-based health care practices and services by providing the infrastructure to leverage community-based clinicians and/or health care delivery systems to conduct research addressing health care for populations that experience health disparities including the diverse clinicians providing health services. The UG3/UH3 Cooperative Agreement involves 2 phases. The UG3 phase, for up to 2 years, is designed to support a project with specific milestones to be accomplished by the end of the period. The UH3 phase is to provide funding for up to 3 additional years following successful completion of the UG3. UG3 projects that meet their milestones will be administratively considered by NIMHD and prioritized for transition to the UH3 phase. Investigators submitting to this FOA must describe both UG3 and UH3 phases.

Funding Opportunity RFA-EY-22-001 from the NIH Guide for Grants and Contracts. The overall purpose of this funding opportunity announcement (FOA) is to invite applicants from multidisciplinary research teams to develop a community-based resource of microbial data associated with the resident ocular microbiome of healthy individuals. Interests also exist in identifying factors microbial communities elaborate that impact human physiology. This announcement will support research projects designed to: delineate and characterize core ocular microbial constituents in the front of the eye; understand their immune and neuro interactions and contributions to the maintenance of homeostasis; and integrate microbiome, omics, and clinical data to determine profiles that promote health of the ocular surface. The front of the eye or anterior segment includes the ocular surface, cornea, iris, ciliary body, conjunctiva, lens, eyelids and periocular skin.

Notice NOT-GM-22-005 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-OD-22-011 from the NIH Guide for Grants and Contracts. The NIH Office of the Director intends to support a Rapid Acceleration of Diagnostics (RADx) Tribal Data Repository (RADx TDR) for American Indian and Alaska Native (AI/AN) data collected from projects supported by the RADx initiative. The RADx TDR data will allow better understanding of the impact of COVID-19, support research to better inform and develop policies to address current and future pandemics, and support and promote researchers, including AI/AN researchers.

Experience with bioinformatic analysis and laboratory information systems preferred. Interacts with medical informatics team to maintain and improve sequence…
From Versiti - Tue, 05 Apr 2022 21:10:53 GMT - View all Milwaukee, WI jobs

Funding Opportunity RFA-CA-22-025 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.

Funding Opportunity RFA-AI-22-020 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for collaborative, multidisciplinary research to develop and optimize next-generation immunological assays that will be readily utilized for influenza clinical studies and trials by the end of the UH2/UH3 project period.

Funding Opportunity RFA-AI-22-028 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics and related countermeasures against antibiotic resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacteriaceae, or Candida auris. Applications must include a Product Development Strategy attachment. Substantive investment by industrial participants is highly encouraged.

Funding Opportunity RFA-CA-22-016 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to solicit applications for the Pediatric Immunotherapy Network (PIN). The overall goal of this FOA is to establish a collaborative network consisting of investigators with relevant expertise to develop and advance novel translational immunotherapy approaches for children and adolescents with solid tumors including brain tumors. This FOA solicits U01 applications for discrete research projects that address relevant research opportunities focused on pediatric solid tumors (e.g., mechanisms of immune evasion, development of pre-clinical models, discovery and validation of novel therapeutic targets, development of novel pediatric immunotherapy agents and treatment approaches such as cancer vaccines, cellular therapy, and combinations with immunotherapy agents. Successful applicants will become members of the Pediatric Immunotherapy Network (PIN), which will address current challenges in pediatric cancer immunotherapy and accelerate the pace at which effective immunotherapies are realized for pediatric solid tumors.

Funding Opportunity RFA-DC-23-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Institute on Deafness and Other Communication Disorders (NIDCD). This program is intended to support Early Stage and New Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences. Principal Investigators (PIs) from categories A-C listed in the NIH Diversity Statement (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-031.html) are especially encouraged to work with their institutions to apply. Preliminary data are not required for this FOA.